Clinically, targeting the OGT-UBAP2L axis with the small-molecule inhibitor OMSI-1 replicates reduced UBAP2L expression, suppressed PI3K-AKT-mTOR signaling, and restored sunitinib sensitivity in resistant ccRCC cells. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.